PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
May 30, 2026Journal of Clinical Oncology

Timing of central nervous system metastases occurrence in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: A single institution real-world analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMartina MatecMKMarija KrižićMPMarina Popović

Discussion

Loading...

Member takes

Overview

Real-world analysis shows varied timing of CNS metastases in hormone receptor-positive metastatic breast cancer, suggesting ongoing treatment efficacy.

Key Points

  • To analyze the timing of central nervous system (CNS) metastases in patients with hormone receptor-positive metastatic breast cancer treated with CDK4/6 inhibitors.
  • Extracted data from medical records of HR+/HER2- MBC patients treated with CDK4/6 inhibitors from April 2018 to December 2025.
  • Stratified patients by timing of CNS metastases development: at baseline, during treatment, or later after progression.
  • Estimated median real-world progression-free survival (rwPFS) using the Kaplan-Meier method.
  • 49 out of 442 patients (11%) developed CNS metastases during metastatic disease.
  • Median rwPFS for patients with baseline CNS metastases was 12.5 months; for those developing them during treatment, it was 30 months.
  • Patients with isolated CNS progression who continued CDK4/6i beyond progression had a median rwPFS of 7 months.

Cite This Study

Matec et al. (2026) studied this question.

synapsesocial.com/papers/6a1a82b80307b785094345cbhttps://doi.org/10.1200/jco.2026.44.16_suppl.e13068
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world treatment patterns and outcomes during and after treatment with CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer.2026
  2. 2Abstract PS1-12-30: Real-world outcomes of first-line cdk4/6 inhibitor use in hr+/her2− metastatic breast cancer: a single-institution experience2026
  3. 3Real-World Data with CDK4/6 Inhibitors—A Single Center Experience from Croatia2024 · 2 citations
  4. 4Abstract PO1-05-01: Cyclin-dependent Kinase 4/6 Inhibitors Combined with Radiotherapy in the Management of Brain Metastases in HR-positive/HER2-negative Breast Cancer Patients2024
  5. 5Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals2026